The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Ann N Y Acad Sci
; 941: 177-84, 2001 Sep.
Article
em En
| MEDLINE
| ID: mdl-11594571
ABSTRACT
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Linfoma Cutâneo de Células T
/
Interleucina-12
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2001
Tipo de documento:
Article